RecallRadar

FDA Drug recall D-0269-2023

Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, packaged in (a) 100-count bottle, NDC 68001-501-00

On 2023-02-22 the FDA classified a Class II recall of Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, packaged in (a) 100-count bottle, NDC 68001-501-00 by Amerisource Health Services, citing failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0269-2023
ClassificationClass II
Statusterminated
Initiated2023-01-11
Published2023-02-22
Last updated2026-09-13 11:52 UTC
CompanyAmerisource Health Services
DistributionUS

Product

Metoprolol Succinate Extended-Release Tablets, USP, 50 mg, packaged in (a) 100-count bottle, NDC 68001-501-00; (b) 500-count bottle, NDC 68001-501-03. Manufactured by Alkem Laboratories Ltd., India. For BluePoint Laboratories

Reason

Failed Dissolution Specifications: This recall is being initiated in support of the recall by the manufacturer which included lots that were packaged for BluePoint Laboratories.

Identifiers

ndc68001-500-00
ndc68001-500-03
ndc68001-500-08
ndc68001-501-00
ndc68001-501-03
ndc68001-501-08
ndc68001-502-00
ndc68001-502-03
ndc68001-502-08
ndc68001-503-00
code_infoLots: (a) 21143211, EXP 03/31/2023; (b) 21143185, 21143193, EXP 02/28/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0269-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.